Cited by 214Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyCAR-T cell therapy research

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Open access

Si, Jingwen, Shi, Xiangjun, Sun, Shuhao, Zou, Bin, Li, Yaopeng, An, Dongjie, Lin, Xingyu, Gao, Yan, Long, Fei, Pang, Bo, Liu, Xing, Liu, Tian, Chi, Wenna, Chen, Ligong, Dimitrov, Dimiter S., Sun, Yan, Du, Xinru, Yin, Wen, Gao, Guangxun, Min, Junxia, Wei, Lai, Liao, Xuebin·2020·Cancer Cell

DOI 10.1016/j.ccell.2020.08.001

Open this paper in CoChat — free account Open PDF

Abstract

Ameliorating T cell exhaustion and enhancing effector function are promising strategies for the improvement of immunotherapies. Here, we show that the HPK1-NFκB-Blimp1 axis mediates T cell dysfunction. High expression of MAP4K1 (which encodes HPK1) correlates with increased T cell exhaustion and with worse patient survival in several cancer types. In MAP4K1KO mice, tumors grow slower than in wild-type mice and infiltrating T cells are less exhausted and more active and proliferative. We further show that genetic depletion, pharmacological inhibition, or proteolysis targeting chimera (PROTAC)-mediated degradation of HPK1 improves the efficacy of CAR-T cell-based immunotherapies in diverse preclinical mouse models of hematological and solid tumors. These strategies are more effective than genetically depleting PD-1 in CAR-T cells. Thus, we demonstrate that HPK1 is a mediator of T cell dysfunction and an attractive druggable target to improve immune therapy responses.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.08.001

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Molecular and cellular insights into T cell exhaustion
Wherry, E. J., & Kurachi, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3862 · Cited by 4,652
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
T cell exhaustion
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Repair of double-strand breaks induced by CRISPR–Cas9 leads to large deletions and complex rearrangements
Kosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
Hidalgo, M. M., Amant, F. C., Biankin, A. V., Budínská, E., Byrne, A. T., Caldas, C., Clarke, R. B., de Jong, S., Jonkers, J., Mælandsmo, G. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0001 · Cited by 1,797
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0010-1 · Cited by 1,785
Defining ‘T cell exhaustion’
Blank, C. U., Haining, W. N., Held, W., Hogan, P. G., Kallies, A., Lugli, E., Lynn, R. C., Philip, M., Rao, A., Restifo, N. P., et al. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0221-9 · Cited by 1,603

Flagged first, then by citations

Show all 45 references

Sorted by citations

PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 695
Advancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 697
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 389
An overview of PROTACs: a promising drug discovery paradigm
Zi, L., Hu, M., Yu, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 380
TRAP1 drives smooth muscle cell senescence and promotes atherosclerosis via HDAC3-primed histone H4 lysine 12 lactylation
Li, X., Chen, M., Chen, X., He, X., Li, X., Wei, H., Tan, Y., Min, J., Azam, T., Xue, M., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae379 · Cited by 220
Self-citation
A knowledge-guided pre-training framework for improving molecular representation learning
Li, H., Zhang, R., Min, Y., Ma, D., Zhao, D. Y., & Zeng, J. (2023) · Nature Communications · doi:10.1038/s41467-023-43214-1 · Cited by 173
The expanding role for small molecules in immuno-oncology
Offringa, R., Kötzner, L., Huck, B. R., & Urbahns, K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00538-9 · Cited by 140
T-cell exhaustion in immune-mediated inflammatory diseases: New implications for immunotherapy
Gao, Z., Feng, Y., Xu, J., & Liang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.977394 · Cited by 118
m6A methylation: a process reshaping the tumour immune microenvironment and regulating immune evasion
Cao, X., Geng, Q., Fan, D., Wang, Q., Wang, X., Zhang, M., Zhao, L., Jiao, Y., Deng, T., Liu, H., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-022-01704-8 · Cited by 115
Mechanisms of CAR T cell exhaustion and current counteraction strategies
Zhu, X., Li, Q., & Zhu, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1034257 · Cited by 106
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy
Bulliard, Y., Andersson, B. S., Baysal, M. A., Damiano, J. S., & Tsimberidou, A. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01504-7 · Cited by 98
Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies
Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 104
Self-citation
Targeted Anti‐Tumor Immunotherapy Using Tumor Infiltrating Cells
Xie, Y., Xie, F., Zhang, L., Zhou, X., Huang, J., Wang, F., Jin, J., Zhang, L., Zeng, L., & Zhou, F. (2021) · Advanced Science · doi:10.1002/advs.202101672 · Cited by 72
The development of small-molecule inhibitors targeting HPK1
Zhou, L., Wang, T., Zhang, K., Zhang, X., & Jiang, S. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114819 · Cited by 72
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
Zhu, Q., Chen, N., Tian, X., Zhou, Y.-L., You, Q., & Xu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00172 · Cited by 70
Characterizing DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy
Li, H., Xu, L., Weisenberger, D. J., Li, M., Zhou, W., Peng, C., Stachelek, K., Cobrinik, D. E., Liang, G., & Berry, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33248-2 · Cited by 70
T Cell Exhaustion and CAR‐T Immunotherapy in Hematological Malignancies
Tang, L., Zhang, Y., Hu, Y., & Mei, H. (2021) · BioMed Research International · doi:10.1155/2021/6616391 · Cited by 72
Small-molecule agents for cancer immunotherapy
Wang, F., Fu, K., Wang, Y., Pan, C., Wang, X., Liu, Z., Yang, C., Zheng, Y. Y., Li, X., Lu, Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.12.010 · Cited by 71
Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds
Vara, B., Levi, S. M., Achab, A., Candito, D. A., Fradera, X., Lesburg, C. A., Kawamura, S., Lacey, B. M., Lim, J., Methot, J. L., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00096 · Cited by 65
Chemically engineering cells for precision medicine
Wang, Y., Li, Z., Mo, F., Chen‐Mayfield, T., Saini, A., LaMere, A. M., & Hu, Q. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00142j · Cited by 62
Targets of tumor microenvironment for potential drug development
Zhang, L., Wang, Z., Liu, K., Liu, Y., Wang, S., Jiang, W., Lu, F., & Dang, Y. (2024) · MedComm – Oncology · doi:10.1002/mog2.68 · Cited by 68
A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer
Han, P.-Z., Ye, W.-D., Yu, P., Tan, L.-C., Xiao Hua, S. H. I., Chen, X.-F., He, C., Hu, J., Wei, W., Lu, Z., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173712 · Cited by 69
Self-citation
Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity
Xu, Y., Wang, X., Li, Y., Mao, Y., Su, Y., Mao, Y., Yang, Y., Gao, W., Fu, C., Chen, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54438-0 · Cited by 68
Self-citation
Astragalus polysaccharide ameliorates CD8+ T cell dysfunction through STAT3/Gal-3/LAG3 pathway in inflammation‐induced colorectal cancer
Li, Q., Zhang, C., Xu, G., Shang, X., Nan, X., Li, Y., Liu, J., Hong, Y., Wang, Q., & Peng, G. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116172 · Cited by 57
Self-citation
Molecular Mechanisms Governing CD8 T Cell Differentiation and Checkpoint Inhibitor Response in Cancer
Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 66
Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)
Linney, I. D., & Kaila, N. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1924671 · Cited by 53
Single‐cell transcriptomics reveal the intratumoral landscape of infiltrated T‐cell subpopulations in oral squamous cell carcinoma
Chen, J., Yang, J., Li, H., Yang, Z., Zhang, X., Li, X., Wang, J., Zhang, Y., Chen, S., & Song, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12910 · Cited by 57
PROTACs: Novel tools for improving immunotherapy in cancer
Li, S., Chen, T., Liu, J., Zhang, H., Li, J., Wang, Z. P., & Shang, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216128 · Cited by 54
FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity
Chen, E., Wu, J., Huang, J., Zhu, W., Sun, H., Wang, X., Lin, D., Li, X., Shi, D., Liu, Z.-Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48397-9 · Cited by 53
The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy
Malchow, S., Korepanova, A. V., Panchal, S. C., McClure, R. A., Longenecker, K. L., Qiu, W., Zhao, H., Cheng, M., Guo, J. Q., Klinge, K. L., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.1c00819 · Cited by 50
Identification of Potent Reverse Indazole Inhibitors for HPK1
Yu, E. C., Methot, J. L., Fradera, X., Lesburg, C. A., Lacey, B. M., Siliphaivanh, P., Liu, P., Smith, D. M., Xu, Z., Piesvaux, J., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00672 · Cited by 46
The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy
Hou, B., Chen, T., Zhang, H., Li, J., Wang, P., & Shang, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123244 · Cited by 45
Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies
Dabiri, H., Kozani, P. S., Habibi‐Anbouhi, M., Godarzee, M. M., Haddadi, M. H., Basiri, M., Ziaei, V., Sadeghizadeh, M., & Saffar, E. H. (2023) · Biomarker Research · doi:10.1186/s40364-023-00509-1 · Cited by 45
Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy
Song, Y., Dong, Q., Ni, Y.-K., Xu, X., Chen, C.-X., & Chen, W. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s448684 · Cited by 47
Reversing Post-Infectious Epigenetic-Mediated Immune Suppression
Abhimanyu, A., Ontiveros, C. O., Guerra-Resendez, R. S., Nishiguchi, T., Ladki, M., Hilton, I. B., Schlesinger, L. S., & DiNardo, A. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.688132 · Cited by 46
Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer
Wang, Q., Ma, X., Wu, H., Zhao, C., Chen, J., Li, R., Yan, S., Li, Y., Zhang, Q., Song, K., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2096362 · Cited by 43
Self-citation
CRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 46
Metabolic adaptation of NK cell activity and behavior in tumors: challenges and therapeutic opportunities
Borde, S., & Matosevic, S. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.08.009 · Cited by 41
Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels
Lv, J., Qin, L., Zhao, R., Wu, D., Wu, Z., Zheng, D., Li, S., Luo, M., Wu, Q., Long, Y., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.12.003 · Cited by 38
Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets
Laletin, V., Bernard, P.-L., Silva, C. C. D., Guittard, G. C., & Nunès, J. A. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005845 · Cited by 40
Progression of m6A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming
Han, X., Zhu, Y., Ke, J., Zhai, Y., Huang, M., Zhang, X., He, H., Zhang, X., Zhao, X., Guo, K., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02092-2 · Cited by 40
Targeting PRMT5 through PROTAC for the treatment of triple-negative breast cancer
Guo, Y., Li, Y., Zhou, Z., Hou, L., Liu, W., Ren, W., Mi, D., Sun, J., Dai, X., Wu, Y., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03237-y · Cited by 39
Self-citation
Exploiting T cell signaling to optimize engineered T cell therapies
Wang, H., Song, X., Shen, L., Wang, X., & Xu, C. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.007 · Cited by 37
Therapeutic strategies targeting uPAR potentiate anti–PD-1 efficacy in diffuse-type gastric cancer
Qin, L., Wang, L., Zhang, J., Zhou, H., Yang, Z., Wang, Y., Cai, W., Wen, F., Jiang, X., Zhang, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn3774 · Cited by 36
Design, Synthesis, and Pharmacological Evaluation of Isoindoline Analogues as New HPK1 Inhibitors
Xie, C.-H., Liu, B., Song, Z., Yang, Y., Dai, M., Gao, Y., Yao, Y.-J., Ding, C., Ai, J., & Zhang, A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01571 · Cited by 35
Self-citation
m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy
Chen, X., Yuan, Y., Zhou, F., Li, L., Pu, J., & Jiang, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06221-y · Cited by 43
Discovery of 7H-Pyrrolo[2,3-d]pyrimidine Derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors
Wu, F., Li, H., An, Q., Sun, Y., Yu, J., Cao, W., Sun, P., Diao, X., Meng, L., & Xu, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115355 · Cited by 32
Self-citation
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor
Reichenbach, P., Attianese, G. M. P. G., Ouchen, K., Cribioli, E., Triboulet, M. M., Ash, S., Saillard, M., de Silly, R. V., Coukos, G., & Irving, M. B. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01013-5 · Cited by 32
Discovery of Pyridine-2-Carboxamides Derivatives as Potent and Selective HPK1 Inhibitors for the Treatment of Cancer
Peng, J., Ding, X., Chen, C. X., Zhao, P., Ding, X., Zhang, M., Aliper, A. M., Ren, F., Lu, H., & Zhavoronkov, A. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02421 · Cited by 29
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy
Wu, M., Wu, Y., Jin, Y., Mao, X., Zeng, S., Yu, H., Zhang, J., Jin, Y., Wu, Y., Xu, T., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00644 · Cited by 27
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors
Shi, H., Tang, H., Li, Y., Chen, D., Liu, T., Chen, Y., Wang, X., Chen, L., Wang, Y., Xie, H., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115064 · Cited by 27
Self-citation
Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
Alvanou, M., Lysandrou, M., Christofi, P., Psatha, N., Spyridonidis, A., Παπαδοπούλου, Α., & Yannaki, E. (2023) · Cancers · doi:10.3390/cancers15071935 · Cited by 28
Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress
Chen, H., Guan, X., He, C., Lü, T., Lin, X., & Liao, X. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2344697 · Cited by 26
Self-citation
Potential mechanisms of cancer stem‐like progenitor T‐cell bio‐behaviours
Ni, L. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1817 · Cited by 26
Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling
Zeng, S., Jin, Y., Xia, H., Shang, Y., Li, Y., Wang, Z., & Huang, W. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.107016 · Cited by 26
Self-citation
Molecular pretraining models towards molecular property prediction
Qiao, J., Gao, W., Jin, J., Wang, D., Xu, G., Manavalan, B., & Wei, L. (2025) · Science China Information Sciences · doi:10.1007/s11432-024-4457-2 · Cited by 28
Self-citation
Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor
Shields, J. D., Baker, D., Balazs, A., Bommakanti, G., Casella, R., Cao, S., Cook, S., Escobar, R. A., Fawell, S. E., Gibbons, F. D., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02631 · Cited by 24
Self-citation
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
Yang, Y. P., Yao, X., Wang, Q., Yang, M., Li, R., Qin, J., Zhuang, J., & Sun, C. (2026) · Advanced Science · doi:10.1002/advs.202520634 · Cited by 27
Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody
Zeng, S., Wu, M., Jin, Y., Ye, Y., Xia, H., Chen, X., Che, J., Wang, Z., Wu, Y., Dong, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116206 · Cited by 23
An Oral PROTAC Targeting HPK1 Degradation Potentiates Anti‐Solid Tumor Immunity
Yao, Y., Wu, M., Wang, Y., Liao, Z., Yang, Y., Liu, Y., Shi, J., Wu, W., Wei, X., Xu, J., et al. (2024) · Advanced Materials · doi:10.1002/adma.202411454 · Cited by 24
Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
Wolska, A., & Smolewski, P. (2022) · Cancers · doi:10.3390/cancers14153778 · Cited by 21
Engineering CRISPR/Cas9 therapeutics for cancer precision medicine
Sharma, A. K., & Giri, A. K. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1309175 · Cited by 23
Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors
Ye, Q., Liu, K., Ye, H., Pan, J., Sokolsky, A., Wang, A., Zhang, K., Hummel, J. R., Kong, L., Behshad, E., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00238 · Cited by 20
Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion
Zeng, S., Zeng, M., Yuan, S., He, L., Jin, Y., Huang, J., yang, M., yang, M., Pan, Y., Wang, Z., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106728 · Cited by 20
Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review)
Hou, R., Wu, X., Wang, C., Fan, H., Zhang, Y., Wu, H., Wang, H., Ding, J., Jiang, H., & Xu, J. (2025) · International Journal of Oncology · doi:10.3892/ijo.2025.5734 · Cited by 19
scMINER: a mutual information-based framework for clustering and hidden driver inference from single-cell transcriptomics data
Pan, Q., Ding, L., Hladyshau, S., Yao, X., Zhou, J., Yan, L., Dhungana, Y., Shi, H., Qian, C., Dong, X., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59620-6 · Cited by 24
Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening
Ge, H., Peng, L., Sun, Z., Liu, H., Shen, Y., & Yao, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.850855 · Cited by 18
Clinical trials and promising preclinical applications of CRISPR/Cas gene editing
Çerçi, B., Uzay, İ. A., Kara, M. K., & Dinçer, P. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121204 · Cited by 19
Potent and Selective Biaryl Amide Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)
Sokolsky, A., Vechorkin, O., Hummel, J. R., Styduhar, E. D., Wang, A., Nguyen, M. H., Ye, H. F., Liu, K., Zhang, K., Pan, J., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00241 · Cited by 18
Opportunities and challenges for targeting HPK1 in cancer immunotherapy
Xu, J., Li, Y., Chen, X., Junyi, Y., Xia, H., Huang, W., & Zeng, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107866 · Cited by 18
Self-citation
The ubiquitin ligase KLHL6 drives resistance to CD8+ T cell dysfunction
Cheng, H., Su, Y., Pan, X., Xu, Y., Xie, E., Du, J., Chen, D. G., Dai, X., Gottardo, R., Greenberg, P. D., et al. (2026) · Nature · doi:10.1038/s41586-025-09926-8 · Cited by 18
An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma
Yang, L. C., Zhao, Q., Chen, T., Liu, W., Qiu, X., Chen, J., Huang, S., Huang, R., & Dong, L. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01068-3 · Cited by 17
Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
Li, Q., Zhou, L., Qin, S., Huang, Z., Li, B., Li, B., Yang, M., Nice, E. C., Zhu, H., & Huang, C. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115447 · Cited by 17
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
Yang, Z., & Wang, Y. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002549 · Cited by 18
Discovery of quinazoline HPK1 inhibitors with high cellular potency
Toure, M., Johnson, T. L., Li, B., Schmidt, R., Ma, H., Neagu, C., Lopez, A. U., Wang, Y., Guler, S. Y., Xiao, Y., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117423 · Cited by 17
High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients
Zhang, J., Ren, Z., Hu, Y. Y., Shang, S., Wang, R., Ma, J., Zhang, Z., Wu, M., Wang, F., Yu, J., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111363 · Cited by 20
Emerging Targets and Therapeutics in Immuno-Oncology: Insights from Landscape Analysis
Iyer, K. A., Ivanov, J. M., Tenchov, R., Ralhan, K., Rodríguez, Y., Sasso, J. M., Scott, S. A., & Zhou, Q. A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00568 · Cited by 20
Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy
Zhang, Z., Guo, L., Zhao, M., Pan, H., Zhao, D., Wang, L., Yang, X., Zhang, Z., Wu, M., Chang, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01906 · Cited by 16
HPK1 citron homology domain regulates phosphorylation of SLP76 and modulates kinase domain interaction dynamics
Chitre, A. S., Wu, P., Walters, B. T., Wang, X., Bouyssou, A., Du, X., Lehoux, I. E., Fong, R., Arata, A., Chan, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48014-9 · Cited by 15
Self-citation
Recent advances in targeting protein degradation for tumor immunotherapy
Li, S., Jin, Y., Wu, H., Yuan, H., & Zhao, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01765-4 · Cited by 14
Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent Hematopoietic Progenitor Kinase 1 (HPK1) inhibitors
Fu, S., Wei, J., Li, C., Zhang, N., Yue, H., Yang, A., Xu, J., Dong, K., Xing, Y., Tong, M., et al. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107454 · Cited by 14
Self-citation
HPK1 Dysregulation‐Associated NK Cell Dysfunction and Defective Expansion Promotes Metastatic Melanoma Progression
Choi, W. S., Kwon, H., Yi, E., Lee, H., Kim, J. M., Park, H. J., Choi, E. J., Choi, M. E., Sung, Y. H., Won, C. H., et al. (2024) · Advanced Science · doi:10.1002/advs.202400920 · Cited by 14
ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation
Zhang, W., Ren, W., Guo, S., Han, H., Cai, W., Bai, H., Li, L., Jiang, X., Zheng, X., Zhang, T., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07905-5 · Cited by 15
Structure-Guided Optimization of 2-Aminoquinazoline Hematopoietic Progenitor Kinase 1 Inhibitors for Improved Oral Bioavailability and Synergistic Antitumor Immunity
Wan, B., Liang, L., Zhong, K., Ma, Y., Wang, H., Wang, Z., Sun, S., Lu, T., Chen, Y., & Zhu, Y. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00762 · Cited by 13
Self-citation
Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors
Qiu, X., Liu, R., Ling, H., Zhou, Y., Ren, X., Zhou, F., Zhang, J., Huang, W., Wang, Z., & Ding, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116310 · Cited by 12
Cell-based relay delivery strategy in biomedical applications
Chen, Y., Pal, S., & Hu, Q. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114871 · Cited by 12
MAP4K signaling pathways in cancer: roles, mechanisms and therapeutic opportunities
Bunardi, C. S., Yeom, M., Kosasih, P., Han, H., Wang, W., & Seo, G. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01544-8 · Cited by 16
Enhancing kinase-inhibitor activity and selectivity prediction through contrastive learning
Tian, Y., Lu, R., Gong, X., Zhao, W., Li, Y., Wang, X., Jia, X., Li, Q., Yang, Y., Tong, H. H. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65869-8 · Cited by 11
Self-citation
Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy
Bridge, J. E., Johnson, M. J., Kar, B., Kim, J., Wenthe, S. J., Krueger, J. B., Wick, B. J., Kluesner, M. G., Crane, A. T., Bell, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.03.007 · Cited by 12
Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1
Zhou, L., Ye, X., Wang, K., Shen, H., Wang, T., Zhang, X., Jiang, S., Xiao, Y., & Zhang, K. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106682 · Cited by 11
Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors
Peng, J., Ding, X., Shih, P.-Y., Meng, Q., Ding, X., Zhang, M., Aliper, A., Ren, F., Lu, H., & Zhavoronkov, A. A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116877 · Cited by 10
Microenvironmental alkalization promotes the therapeutic effects of MSLN-CAR-T cells
Wu, M., Mao, L., Zhai, X., Liu, J., Wang, J., Li, L., Duan, J., Wang, J., Lin, S. J., Li, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009510 · Cited by 11
Discovery of 1,2,4-benzotriazine derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors
Mao, J., Zhou, L., Wu, Y., Wang, K., Ye, X., Wang, T., Yang, J., Tong, J., Miao, Q., Jiang, S., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108158 · Cited by 10
Highly selective HPK1 inhibitor NDI-101150 mediates immune cell activation and robust antitumor responses, distinct from immune checkpoint blockade
Ciccone, D. N., Kuo, F., Boiko, S., Carreiro, S. T., Kaila, N., McElwee, J. J., Tummino, P. J., & Loh, C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012064 · Cited by 10
Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy
Hu, X., Li, E., Zhou, Y., You, Q., & Jiang, Z. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117677 · Cited by 10
A systematic review of gene editing clinical trialsPreprint
Eshka, S. F. A., Bahador, M., Gordan, M. M., Karbasi, S., Tabar, Z. M., & Basiri, M. (2022) · medRxiv · doi:10.1101/2022.11.24.22282599 · Cited by 10
Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration
Sun, J., Fan, H., Zhu, Y., Pan, T., Wu, Y., Zhang, D.-Y., & Hou, X. (2023) · Life Science Alliance · doi:10.26508/lsa.202301966 · Cited by 9
Targeting T-cell Aging to Remodel the Aging Immune System and Revitalize Geriatric Immunotherapy
Mi, C., Zhou, S., & Xue, J. (2025) · Aging and Disease · doi:10.14336/ad.2025.0061 · Cited by 10

Authors: Si, J., Shi, X., Sun, S., Zou, B., Li, Y., An, D., Lin, X., Gao, Y., Long, F., Pang, B., Liu, X., Liu, T., Chi, W., Chen, L., Dimitrov, D. S., Sun, Y., Du, X., Yin, W., Gao, G., Min, J., Wei, L., & Liao, X.
Affiliations: National Institute of Biological Sciences, Beijing (CN)
Tsinghua University (CN)
Sun Yat-sen University (CN)
Capital Medical University (CN)
China Academy of Chinese Medical Sciences (CN)
Central South University (CN)
University of Pittsburgh (US)
Lanzhou Institute of Husbandry and Pharmaceutical Sciences (CN)
Beijing Chao-Yang Hospital, Capital Medical University (CN)
Xijing Hospital (CN)
First Affiliated Hospital Zhejiang University (CN)
Corresponding author: Wei, Lai
Liao, Xuebin
ORCID: Si, Jingwen
Shi, Xiangjun
Sun, Shuhao
Zou, Bin
Li, Yaopeng
An, Dongjie
Lin, Xingyu
Gao, Yan
Long, Fei
Pang, Bo
Liu, Xing
Chi, Wenna
Chen, Ligong
Dimitrov, Dimiter S.
Sun, Yan
Du, Xinru
Gao, Guangxun
Min, Junxia
Wei, Lai
Liao, Xuebin
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2020-10
Volume: 38
Issue: 4
Pages: 551-566.e11
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2020.08.001
OpenAlex: W3081763916
Semantic Scholar: 40ab8b396854539d254f72dff6f7a6a9b2af7c39
Cited by: 209
References: 45
Citations by year: 2026: 40 · 2025: 49 · 2024: 39 · 2023: 42 · 2022: 24 · 2021: 15
FWCI: 7.58
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 376 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: Tsinghua University (PCT/CN2019/083499)
Ministry of Science and Technology of the People's Republic of China (2015CB943201)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords: HPK1, MAP4K1, T cell exhaustion, T cell dysfunction, NF-κB, Blimp-1, CAR T-cell therapy, cancer immunotherapy, hematologic cancer, solid tumors, PD-1
MeSH terms: Animals, Humans, Immunotherapy, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasms, T-Lymphocytes, Mice, SCID, Mice, Inbred NOD, Protein Serine-Threonine Kinases, Mice, Knockout, Jurkat Cells, K562 Cells, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks